Prolonged antidiabetic effect of zinc-crystallized insulin loaded glycol chitosan nanoparticles in type 1 diabetic rats

Archives of Pharmacal Research

Volumn 31, Issue 7, 2008, Pages 918-923

  Jo, Hyung Gon ^a   Min, Kyung Hyun ^a   Nam, Tae Hwan ^a   Na, Seong Ju ^a   Park, Jae Hyung ^a   Jeong, Seo Young ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Basal insulin; Blood glucose control; Nanoparticles; Type 1 diabetes

Indexed keywords

ANTIDIABETIC AGENT; CHITOSAN; DRUG CARRIER; DRUG DERIVATIVE; GLYCOL; INSULIN; NANOPARTICLE;

ANIMAL; AREA UNDER THE CURVE; ARTICLE; BLOOD; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; RAT; SOLUBILITY; SPRAGUE DAWLEY RAT;

ANIMALS; AREA UNDER CURVE; BLOOD GLUCOSE; CHITOSAN; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG CARRIERS; GLYCOLS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 49749133132     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-001-1247-9     Document Type: Article

References (16)

1. Agu, R. U., Ugwoke, M. I., Armand, M., Kinget, R., and Verbeke, N., The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res, 2, 198-209 (2001).
2. Binder, C., T. Lauritzen, Faber, O., and Pramming, S., Insulin pharmacokinetics. Diabetes Care, 7, 188-199 (1984).
3. Brange, J. and Volund, A., Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev, 35, 307-335 (1999).
4. Cefalu, W. T., Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care, 27, 239-246 (2004).
5. Frokjaer, S. and D. E. Otzen, Protein drug stability: a formulation challenge. Nat Rev Drug Discov, 4, 298-306 (2005).
6. Gershonov, E., Shechter, Y., and Fridkin, M. New concept for long-acting insulin: spontaneous conversion of an inactive modified insulin to the active hormone in circulation: 9-fluorenylmethoxycarbonyl derivative of insulin, Diabetes 48, 1437-1442 (1999).
7. Hamilton-Wessler, M., Ader, M., Dea, M., Moore, D., Jorgensen, P. N., Markussen, J., and Bergman, R. N., Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. Diabetologia, 42, 1254-1263 (1999).
8. Hans, M. L. and Lowman, A. M., Biodegradable nanoparticles for drug delivery and targeting. Current Opinion in Solid State & Materials Science, 6, 319-327 (2002).
9. Kim, J. H., Kim, Y. S., Kim, S., Park, J. H., Kim, K., Choi, K., Chung, H., Jeong, S. Y., Park, R. W., Kim, I. S., and Kwon, I. C., Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J Control Release, 111, 228-234 (2006).
10. Kwon, S., Park, J. H., Chung, H., Kwon, I. C., and Jeong, S. Y., Physicochemical characteristics of self-assembled nanoparticles based on glycol chitosan bearing 5-cholanic acid. Langmuir, 19(24), 10188-10193 (2003).
11. McKeage, K. and Goa, K. L. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus, Drugs, 61, 1599-1624 (2001).
12. Owens, D. R., New horizons-alternative routes for insulin therapy. Nat Rev Drug Discov, 1, 529-540 (2002).
13. Park, J. H., Y. W. Cho, Chung, H., Kwon, I. C., and Jeong, S. Y., Synthesis and characterization of sugar-bearing chitosan derivatives: aqueous solubility and biodegradability. Biomacromolecules, 4, 1087-1091 (2003).
14. Sinha, V. R., A. K. Singla, Wadhawan, S., Kaushik, R., Kumria, R., Bansal, K., and Dhawan, S., Chitosan microspheres as a potential carrier for drugs. Int J Pharm, 274, 1-33 (2004).
15. Skyler, J. S. Lessons from studies of insulin pharmacokinetics. Diabetes Care, 9, 666-668 (1986).
16. Wearley, L. L., Recent progress in protein and peptide delivery by noninvasive routes. Crit Rev Ther Drug Carrier Syst, 8, 331-394 (1991).